{"schema_version":"secwatch.filing_event.v1","accession":"0001384101-25-000128","form_type":"8-K","ticker":"VCYT","cik":"0001384101","company_name":"VERACYTE, INC.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.274250+00:00","generated_at":"2026-05-17T00:35:11.478333+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Veracyte Q3 revenue up 14% to $131.9M, raises FY guidance; adjusted EBITDA margin 30%","bullets":["Total revenue $131.9M (+14% YoY); testing rev $127.8M (+17%); GAAP net income $19.1M.","Decipher revenue $82.2M (+26%); Afirma $43.2M (+7%); total testing volume +19% to 43,679.","Adjusted EBITDA $39.7M (30% margin); cash from ops $44.8M; cash & equivalents $366.4M.","Raised FY2025 total revenue guidance to $506-510M; testing rev guidance $484-487M (+16%).","Completed enrollment of Percepta Nasal Swab NIGHTINGALE trial; upcoming TrueMRD and Prosigna LDT launches."],"urls":{"canonical":"https://secwatch.observer/filing/0001384101-25-000128","json":"https://secwatch.observer/filing/0001384101-25-000128.json","markdown":"https://secwatch.observer/filing/0001384101-25-000128.md","text":"https://secwatch.observer/filing/0001384101-25-000128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1384101/000138410125000128/0001384101-25-000128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1384101/000138410125000128/vcyt-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:35:11.478333+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}